Advanced Glycation End Products As Risk Factors For Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$80,040.00
Summary
There is no cure for type 1 diabetes which manifests in children and adolescents resulting in the need for 5 injections of insulin each day. During this scholarship period, we aim to discover new genetic and blood biomarkers for disease onset in children for use in new born and childhood screening. In addition we will determine if specific environmental factors called advanced glycation end products can contribute to type 1 diabetes via interactions with a specific gene, RAGE.
Identification Of Key Enzymes Required For Efficient Post-translational Modification And Multimerisation Of Adiponectin
Funder
National Health and Medical Research Council
Funding Amount
$92,364.00
Summary
Obesity is a major national and global health issue, with 62% of adult Australians being overweight/obese, associated with a number of diseases such as type 2 diabetes and cardiovascular disease. Fat tissue secretes hormones and dysregulation of these hormones contributes to the development of obesity-associated disease. This project aims to define processes governing the secretion of one key hormone and ultimately to identify targets for the treatment of obesity-associated complications.
ACTIVATION OF ISLET INFLAMMATION BY CYTOKINE SIGNALING IN PANCREATIC BETA CELLS
Funder
National Health and Medical Research Council
Funding Amount
$406,838.00
Summary
Type 1 diabetes affects up to 4.7 million people world-wide and its incidence is increasing. It is the result of killing of insulin-producing pancreatic beta cells by cells of the immune system. This project aims to understand how immune cell invasion of the pancreas can become worse because of protein interactions that occur within beta cells, and how these cells can contribute to their own demise.
Ciliary Neurotrophic Factor: A Novel Theraputic Agent For The Prevention Of Muscle Insulin Resistance
Funder
National Health and Medical Research Council
Funding Amount
$602,673.00
Summary
In 1995 leptin was discovered and scientists world-wide hoped that this was the great panacea in the treatment of obesity related disorders. Alas, from 1995-1997 the identification of a novel cytokine inducible compound termed suppressor of cytokine signaling (SOCS) that negatively regulated leptin signalling and lead to leptin resistance, quashing hopes for a viable anti-obesogenic drug. Recently, however, work from our group has demonstrated that the neuropoietic cytokine, ciliary neurotrophic ....In 1995 leptin was discovered and scientists world-wide hoped that this was the great panacea in the treatment of obesity related disorders. Alas, from 1995-1997 the identification of a novel cytokine inducible compound termed suppressor of cytokine signaling (SOCS) that negatively regulated leptin signalling and lead to leptin resistance, quashing hopes for a viable anti-obesogenic drug. Recently, however, work from our group has demonstrated that the neuropoietic cytokine, ciliary neurotrophic factor (CNTF), can act in an anti-obesogenic fashion in a manner similar to leptin. However, unlike leptin, when we place rodents on a high fat diet, the effects of CNTF persist and override induction SOCS proteins. This project will examine the biochemical pathways that allow the actions of CNTF to persist in the presence of diet-induced obesity. This is of major significance because in completing this work, the potential for the development of peripheral tissue drug targets for the treatment of obesity related diseases are both tangible and realistic.Read moreRead less
Targeting Skeletal MTORC1 As A Novel Approach For The Treatment Of Diet-induced Insulin Resistance
Funder
National Health and Medical Research Council
Funding Amount
$586,979.00
Summary
Diet-induced insulin resistance is a pathology that underlies type 2 diabetes. Elucidating the pathways and tissues that contribute to this condition is crucial for drug development. The skeleton has emerged as a critical insulin target tissue. We provide evidence that suppression of mTORC1, a complex over-activated by nutrients, in bone cells improves insulin sensitivity. In this study, we will determine if blocking mTORC1 function in bone cells can treat diet-induced insulin resistance.
Signaling Pathways To Enhance Potency Of AMPK-targeting Drugs
Funder
National Health and Medical Research Council
Funding Amount
$661,966.00
Summary
Sedentary lifestyles and consumption of high energy foods has led to epidemics of obesity-related metabolic diseases that place enormous financial and medical burden on the Australian economy. An attractive drug target to treat these diseases is AMP-activated protein kinase (AMPK) which functions as both a cellular fuel gauge and co-ordinator of whole-body metabolism. Our goal is to improve AMPK drug potency by identifying novel processes that sensitize AMPK to drugs.
The Role Of Estrogen-receptor Alpha (ERa) In The Pathogenesis Of Diabetes And Cardiovascular Disease.
Funder
National Health and Medical Research Council
Funding Amount
$374,757.00
Summary
Cardiovascular disease (CVD), including heart attack and stroke, causes more deaths in Australia than any other disease. A major risk factor for CVD is diabetes, which affects more than 1 million Australians. Therefore, treating diabetes will reduce the number of people likely to die from CVD. This project aims to investigate a recently identified role for estrogen in the protection against diabetes. If successful, findings from this project may lead to new treatments against diabetes and CVD.
Exploring The Role Of Glycogen Structure In Type 2 Diabetes.
Funder
National Health and Medical Research Council
Funding Amount
$367,126.00
Summary
The incidence of type 2 diabetes, a disease hallmarked by poor blood glucose control, is rapidly increasing in Australia. This project will investigate the role of liver-glycogen, our blood glucose buffer, in the pathology type 2 diabetes, with particular focus on the glycogen’s structure. By determining the importance of glycogen structure on its properties and how this affects diabetic’s blood glucose levels will potentially result in new drug target for the treatment of type 2 diabetes.
Alterations In Secretion And Gene Expression In Pancreatic Beta Cells Exposed To Lipid.
Funder
National Health and Medical Research Council
Funding Amount
$425,250.00
Summary
The project is aimed at a better understanding of the way in which fats control gene expression in the pancreatic beta cells of the islets of Langerhans. Because changes in gene expression are to likely to explain why exposure of these cells to fat disrupts their ability to release insulin, identification of these genes could explain why only some obese people develop Type 2 diabetes.
AMPK Control Of Lipid Metabolism: Role In Regulating Energy Balance And Insulin Sensitivity
Funder
National Health and Medical Research Council
Funding Amount
$614,437.00
Summary
The control of appetite and maintenance of a lean body mass along with exercise is important for protecting the body against obesity and increased incidence of Type 2 diabetes and cardiovascular disease. We are investigating how the regulation of lipid metabolism controls appetite and body weight and the extent to which these same controls are important for drugs acting to lower blood lipid levels.